NDAINTRAVENOUSSOLUTION
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GALLIUM GA 68 EDOTREOTIDE (edotreotide gallium ga-68) by Imagin Medical is 68 dotatoc binds to somatostatin receptors, with highest affinity (k i = 2. First approved in 2019.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GALLIUM GA 68 EDOTREOTIDE is a PET imaging agent that binds to somatostatin receptors (SSTR2) on neuroendocrine tumor cells, enabling diagnostic visualization via positron emission tomography. The Gallium-68 radionuclide emits positrons that produce 511 keV annihilation photons for high-resolution imaging. It is used to localize and characterize somatostatin receptor-expressing malignancies, particularly neuroendocrine tumors.
LOE Approaching2mo to LOE
Product is at peak lifecycle stage with 0.2 years until patent expiration (August 2026), signaling imminent brand transition and likely consolidation of commercial support.
Mechanism of Action
68 DOTATOC binds to somatostatin receptors, with highest affinity (K i = 2.5± 0.5 nanomolar) for subtype 2 receptors (sstr2). Ga 68 DOTATOC binds to cells that express somatostatin receptors including malignant neuroendocrine cells, which overexpress sstr2 receptors. Gallium 68 is a β+ emitting…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on EDOTREOTIDE GALLIUM GA-68 offers exposure to specialized nuclear medicine and rare disease oncology markets, but career progression is constrained by imminent patent expiration and limited clinical pipeline activity. Professionals should expect rapid transition to defensive or post-LOE strategies within 6-12 months, limiting long-term brand growth opportunities.
Brand Manager
Worked on GALLIUM GA 68 EDOTREOTIDE at Imagin Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.